Retraction: Alpha-Fetoprotein Promoter-Driven Cre/LoxP-Switched RNA Interference for Hepatocellular Carcinoma Tissue-Specific Target Therapy
Format: | Article |
---|---|
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697611/?tool=EBI |
Similar Items
-
Retraction: Alpha-Fetoprotein Promoter-Driven Cre/LoxP-Switched RNA Interference for Hepatocellular Carcinoma Tissue-Specific Target Therapy.
by: PLOS ONE Editors
Published: (2023-01-01) -
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
by: Yuan-Fei Peng, et al.
Published: (2013-01-01) -
Cre/loxP-Based Reversible Immortalization of Human Hepatocytes
by: Naoya Kobayashi M.D., Ph.D., et al.
Published: (2001-05-01) -
CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
by: Dominique J. Laster, et al.
Published: (2023-08-01) -
Cre-LoxP-regulated expression of monoclonal antibodies driven by an ovalbumin promoter in primary oviduct cells
by: Esteban Concepcion, et al.
Published: (2011-01-01)